SG Americas Securities
DNTH icon

SG Americas Securities’s Dianthus Therapeutics DNTH Stock Holding History

SG Americas Securities’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$588K Sell
7,007
-11,558
-62% -$669K ﹤0.01% 2091
2025
Q4 		$765K Buy
+18,565
New +$720K ﹤0.01% 2226
2025
Q2 		– Sell
-7,101
Closed -$129K – 3098
2025
Q1 		$129K Sell
7,101
-2,552
-26% -$56.2K ﹤0.01% 2856
2024
Q4 		$210K Buy
9,653
+814
+9% +$20.9K ﹤0.01% 2109
2024
Q3 		$242K Buy
8,839
+4,506
+104% +$126K ﹤0.01% 2340
2024
Q2 		$112K Buy
+4,333
New +$104K ﹤0.01% 2482
2021
Q4 		– Sell
-915
Closed -$107K – 3482
2021
Q3 		$107K Buy
+915
New +$107K ﹤0.01% 3636
2020
Q3 		– Sell
-631
Closed -$76K – 2878
2020
Q2 		$76K Buy
+631
New +$88.9K ﹤0.01% 3452

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SG Americas Securities's DNTH Position: Q1 2026 in Review

SG Americas Securities reduced its Dianthus Therapeutics (DNTH) stake by 62% in Q1 2026, selling an estimated $669K and leaving 7,007 shares worth $588K. The position accounts for ﹤0.01% of the portfolio, ranked #2091.

SG Americas Securities first reported a position in DNTH in Q2 2020 and has held it in 8 quarters since. The position peaked at $765K in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • SG Americas Securities held 7,007 shares of Dianthus Therapeutics worth $588K as of Q1 2026.
  • SG Americas Securities sold 11,558 Dianthus Therapeutics shares in Q1 2026, an estimated $669K.
  • Dianthus Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2091 holding.
  • SG Americas Securities first reported a position in Dianthus Therapeutics in Q2 2020 and has held it in 8 quarters since.
  • SG Americas Securities's Dianthus Therapeutics position peaked at $765K in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.